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ABBREVIATIONS PAGE 
 
TTV: Torque Teno Virus  
OLT: orthotopic liver transplantation 
STCS: Swiss Transplant Cohort Study 
PCR: Polymerase chain reaction 
HC: healthy controls 
DNA: Deoxyribonucleic acid  
HBV: Hepatitis B virus 
HCV: Hepatitis C virus 
HIV: Human immunodeficiency virus 
DSA: donor-specific antibodies 
HR: Hazard ratio  
CI: Confidence interval  
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Replication of Torque teno virus (TTV), a nonpathogenic, highly prevalent 
Anellovirus increases considerably during immunesuppression
1,2
. Recently, Schiemann and 
coworkers published the inverse association of TTV load with rejection after kidney 
transplantation
3
. We here report similar findings in 39 patients [median age 60 (range 1-73) 
years, male 59%] enrolled in the Swiss Transplant Cohort Study (STCS) after orthotopic liver 
transplantation (OLT) for liver disease of viral (33%), toxic (10%) or other (57%) origins.  
 
We measured TTV-DNA levels by real time PCR
4
 at time of transplantation and, at 6 
and 12 months posttransplant for the 19 patients with available serum samples. Seventy-four 
healthy subjects served as controls (HC). TTV-DNA was detectable (detection limit 25 viral 
copies/ml of plasma) in 29/39 (74%) patients at transplantation, a prevalence similar to the 
one observed in controls (51/74, 69%; p=0.8035, 
2
 test). However, median TTV-DNA 
levels were significantly higher in OLT recipients (median 4.54x10
3
 copies/ml, range 25-
1.2x10
8
) compared with controls (median 1.7x10
2 
copies/ml, range 25-5.4x10
4
; p=0.0014, 
Mann–Whitney U test) [Figure 1A]. As shown previously 1,2, TTV-titers in OLT recipients 
increased significantly after transplantation (median 2x10
6
, range 25-5.4x10
8
 at 6 months and 
median 2.2x10
5
, range 25-1.7x10
7
 at 12 months) [Figure 1A]. We further assessed the 
relationship between TTV-loads at transplantation with the risk of biopsy proven acute 
cellular graft rejection (Rejection Activity Index score 3 or 2 with significant necrosis) 
during the first year after transplantation. Interestingly, 1-year cumulative incidence of 
rejection in OLT recipients with detectable TTV-DNA plasma levels at transplantation was 
significantly lower [21% (95%CI 8%-37%)] than in patients with undetectable TTV-titers 
[70% (95%CI 28%-90%); p=0.0042, Gray test; Figure 1B].  
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To account for factors with potential impact on TTV replication and rejection such as 
age, gender, HBV, HCV and HIV serostatus, underlying disease, number of 
immunosuppressive drugs used, hepatic encephalopathy and presence of human leukocyte 
antigen donor-specific antibodies (DSA), we performed a multivariate analysis using Fine-
Gray proportional hazard regression for competing events. This analysis confirmed the 
reduced 1-year cumulative incidence of rejection in patients with detectable TTV titers at 
time of transplantation [HR 9x10
-3 
(95%CI 1x10
-3
-9.2x10
-2
; p=0.00008)].  
 
Our results in OLT recipients are in agreement with those reported by Schiemann for 
kidney transplant recipients and reinforce the results of De Vlaminck and coworkers who 
found that anellovirus levels in heart and lung transplant recipients with acute rejection 
episodes were lower than in nonrejecting patients
5
. It is tempting to speculate that a higher 
immunocompetence in TTV-negative patients at transplantation could be responsible for the 
higher incidence of rejection episodes observed during the first year after transplantation.  
 
Obviously, our study presents several limitations. First, because serological testing for 
TTV is currently unavailable, we cannot exclude that some patients are TTV-negative simply 
because they never have been infected. We do believe however, that the high prevalence of 
TTV in the population makes this unlikely. Second, the study remains somewhat incomplete 
because the lack of posttransplant serum samples precluded the analysis of a potential 
prognostic value of TTV titers after OLT. Larger prospective studies with more patients than 
in our retrospective pilot study are needed to assess whether monitoring TTV-titers could 
help identifying patients at higher risk of acute rejection after OLT.  
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FIGURE LEGEND  
 
Figure 1. TTV load kinetics and impact on the frequency of rejection episodes after 
OLT. A) TTV-DNA titers in OLT recipients (filled dots) compared to healthy controls (HC, 
white dots). Gray filled dots identify patients analyzed at time of transplantation (M0) 
exclusively. Black filled dots identify patients analyzed at time of transplantation (M0), 6 
(M6) and 12 months (M12) after transplantation. Comparison was performed using the 
Mann–Whitney U test and p values are indicated when significant (p<0.05). B) One-year 
biopsy proven acute rejection cumulative incidence in patients displaying detectable (gray 
line) and undetectable (black line) TTV-DNA at transplantation. Cumulative incidence of 
rejection analysis was performed using Gray test with death without rejection as a competing 
event.  
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Figure 1 
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